Your browser doesn't support javascript.
loading
Skin-Derived ABCB5+ Mesenchymal Stem Cells for High-Medical-Need Inflammatory Diseases: From Discovery to Entering Clinical Routine.
Niebergall-Roth, Elke; Frank, Natasha Y; Ganss, Christoph; Frank, Markus H; Kluth, Mark A.
Afiliación
  • Niebergall-Roth E; TICEBA GmbH, 69120 Heidelberg, Germany.
  • Frank NY; Department of Medicine, VA Boston Healthcare System, Boston, MA 02132, USA.
  • Ganss C; Division of Genetics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
  • Frank MH; Harvard Stem Cell Institute, Harvard University, Cambridge, MA 02138, USA.
  • Kluth MA; Transplant Research Program, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Int J Mol Sci ; 24(1)2022 Dec 21.
Article en En | MEDLINE | ID: mdl-36613507
The ATP-binding cassette superfamily member ABCB5 identifies a subset of skin-resident mesenchymal stem cells (MSCs) that exhibit potent immunomodulatory and wound healing-promoting capacities along with superior homing ability. The ABCB5+ MSCs can be easily accessed from discarded skin samples, expanded, and delivered as a highly homogenous medicinal product with standardized potency. A range of preclinical studies has suggested therapeutic efficacy of ABCB5+ MSCs in a variety of currently uncurable skin and non-skin inflammatory diseases, which has been substantiated thus far by distinct clinical trials in chronic skin wounds or recessive dystrophic epidermolysis bullosa. Therefore, skin-derived ABCB5+ MSCs have the potential to provide a breakthrough at the forefront of MSC-based therapies striving to fulfill current unmet medical needs. The most recent milestones in this regard are the approval of a phase III pivotal trial of ABCB5+ MSCs for treatment of recessive dystrophic and junctional epidermolysis bullosa by the US Food and Drug Administration, and national market access of ABCB5+ MSCs (AMESANAR®) for therapy-refractory chronic venous ulcers under the national hospital exemption pathway in Germany.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Epidermólisis Ampollosa Distrófica / Células Madre Mesenquimatosas Límite: Humans País/Región como asunto: America do norte / Europa Idioma: En Revista: Int J Mol Sci Año: 2022 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Epidermólisis Ampollosa Distrófica / Células Madre Mesenquimatosas Límite: Humans País/Región como asunto: America do norte / Europa Idioma: En Revista: Int J Mol Sci Año: 2022 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Suiza